Shamir Geller1, Emily Lebowitz2, Melissa P Pulitzer3, Steven M Horwitz4, Alison J Moskowitz4, Steve Dusza5, Patricia L Myskowski6. 1. Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Electronic address: shamirgeller@gmail.com. 2. Weill Cornell Medical College, New York, New York. 3. Weill Cornell Medical College, New York, New York; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 6. Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York.
Abstract
BACKGROUND: The prevalence of mycosis fungoides/Sézary syndrome (MF/SS) is higher in the black population than in the white population in the United States and worse outcomes have been observed in black patients. OBJECTIVE: To describe the outcomes and to identify prognostic factors in African American and black patients with MF/SS. METHODS: Clinical features and follow-up data were analyzed in 157 self-identified African American or black patients seen during 1994-2018. RESULTS: We included 122 patients with early stage MF and 35 patients with advanced-stage disease (median follow-up of 25 months). Overall, >80% of the patients who died from disease or progressed had erythema or hyperpigmentation without hypopigmentation. Patients with hypopigmentation, either as the sole manifestation or in combination with other lesions, had better overall survival (P = .002) and progression-free survival (P = .014). Clinical stage, TNMB classification, plaque disease, and elevated serum lactate dehydrogenase were also significantly associated with outcomes. Demographic and socioeconomic parameters were not associated with prognosis. LIMITATIONS: A retrospective study at a single cancer center. CONCLUSION: MF/SS manifestations and outcomes in African American and black patients are heterogeneous. Demographic and socioeconomic factors do not seem to have a prognostic role, while clinical characteristics might help in the stratification of risk of progression and shorter survival, allowing for individually tailored therapeutic interventions.
BACKGROUND: The prevalence of mycosis fungoides/Sézary syndrome (MF/SS) is higher in the black population than in the white population in the United States and worse outcomes have been observed in black patients. OBJECTIVE: To describe the outcomes and to identify prognostic factors in African American and black patients with MF/SS. METHODS: Clinical features and follow-up data were analyzed in 157 self-identified African American or black patients seen during 1994-2018. RESULTS: We included 122 patients with early stage MF and 35 patients with advanced-stage disease (median follow-up of 25 months). Overall, >80% of the patients who died from disease or progressed had erythema or hyperpigmentation without hypopigmentation. Patients with hypopigmentation, either as the sole manifestation or in combination with other lesions, had better overall survival (P = .002) and progression-free survival (P = .014). Clinical stage, TNMB classification, plaque disease, and elevated serum lactate dehydrogenase were also significantly associated with outcomes. Demographic and socioeconomic parameters were not associated with prognosis. LIMITATIONS: A retrospective study at a single cancer center. CONCLUSION: MF/SS manifestations and outcomes in African American and black patients are heterogeneous. Demographic and socioeconomic factors do not seem to have a prognostic role, while clinical characteristics might help in the stratification of risk of progression and shorter survival, allowing for individually tailored therapeutic interventions.
Authors: Yevgeniy Balagula; Stephen W Dusza; John Zampella; Ronald Sweren; Ginette A Hinds Journal: J Am Acad Dermatol Date: 2014-09 Impact factor: 11.527
Authors: Ayal A Aizer; Tyler J Wilhite; Ming-Hui Chen; Powell L Graham; Toni K Choueiri; Karen E Hoffman; Neil E Martin; Quoc-Dien Trinh; Jim C Hu; Paul L Nguyen Journal: Cancer Date: 2014-02-22 Impact factor: 6.860
Authors: Pamela B Allen; Subir Goyal; Tim Niyogusaba; Colin O'Leary; Amy Ayers; Erica S Tarabadkar; Mohammad K Khan; Mary Jo Lechowicz Journal: JAMA Dermatol Date: 2022-09-07 Impact factor: 11.816
Authors: Xochiquetzal U Martinez; Arnab Chowdhury; Tracey Stiller; Joycelynne Palmer; Matthew Loscalzo; Estella Barrios; Farah R Abdulla; Jasmine Zain; Steven T Rosen; Christiane Querfeld Journal: Support Care Cancer Date: 2021-05-07 Impact factor: 3.603